Last checked at 
LONDON (Alliance News) - The following stocks are amongst the biggest risers and fallers within the main London indices midday Friday.
-------
FTSE 100 WINNERS
-------
GlaxoSmithKline, up 1.7%. The company said it has received positive results from a phase III study investigating the combination of dabrafenib and trametinib. Glaxo said the overall survival rates from the combination of the drugs showed a statistically significant fall in the risk of death from combining the pair in comparison to dabrafenib monotherapy in patients with BRAF V600E/K mutation-positive metastatic melanoma.
Capita, up 1.2%. The outsourcing company said it has been approved to join the lead provider framework for NHS England's commissioning support services. Capita said clinical commissioning groups in the UK will be required to re-procure many support services by April 2016 in order to comply with European procurement law. Capita said NHS England anticipates this will result in GBP3 billion to GBP5 billion in services being procured through the framework.
-------
FTSE 100 LOSERS
-------
Barrat Developments, down 2%. Liberum has cut the housebuilder to Hold from Buy, but is raising its price target to 498 pence from 439p.
Compass Group, down 1.9%. Goldman Sachs has cut the catering and outsourcing company to Sell from Neutral, but raised its price target to 1,005p from 980p.
-------
FTSE 250 WINNERS
-------
Poundland, up 10.4%. The discount retailer has snapped up rival 99p Stores for GBP55 million in cash and shares. It will pay GBP47.5 million in cash for its fellow high-street discounter, along with a further GBP7.5 million in shares. Based on its closing price of 357.8 pence on Thursday, that would see Poundland issue 2.1 million shares. The deal will be conditional upon the approval of the UK Competition and Markets Authority, and Poundland has conceded it may have to offer concessions to get the deal passed after initial talks with the regulator.
Premier Farnell, up 3.5%. N+1 has raised the technology company's recommendation to Buy from Sell, whilst cutting its price target to 180 pence from 220p, saying the share price fall following the company's disappointing full-year trading update was "too harsh". The stock fell 6.7% on Thursday.
-------
FTSE 250 LOSERS
-------
Tate & Lyle, down 11.7%. The sugar company said it expects its full year profit to fall below its previous guidance on the back of continuing problems in its bulk ingredients business and said it will take action to try and improve its operation and supply chain following prolonged issues.
Lonmin, down 2.8%. JP Morgan has cut the platinum producer to Neutral from Overweight, and its price target to 190p from 280p.
-------
AIM ALL-SHARE WINNERS
-------
Clean Air Power, up 40%. The company said it has been given a certificate of conformity from the US Environmental Protection Agency for its US Genesis EDGE Dual-Fuel compression-ignited natural gas engine. The certificate means the product meets EPA emissions requirements and is valid in 49 of the country's 50 states. It has also submitted a separate application to the California Air Resources Board.
-------
AIM ALL-SHARE LOSERS
-------
Powerhouse Energy Group, off 14%. The company said it has ceased all of its operations in Switzerland and Germany so it can solely focus on the construction of the company's gasification system in Australia. The company said it will put all of its efforts into constructing the newly designed PHE G-3 UHT gasification system in Australia, and the contract opportunities that stem from it.
Holders Technology, down 9.3%. The group said it swung to a loss in its last financial year on the back of a fall in revenue which outpaced lower costs. Holders, which suppliers laminates and materials for printed circuit boards and provides LED services, recorded a pretax loss of GBP362,000 for the year to November 30, compared with a GBP73,000 profit in the previous year.
--------
By Daniel Ruiz; danielruiz@alliancenews.com
Copyright 2015 Alliance News Limited. All Rights Reserved.
Today 19:57
GSK knew about Zantac cancer risk, attorneys tell jury in first trial
May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.
Read more